Morgans analyst Iain Wilkie discusses the healthcare team's initiation of coverage for Antisense Therapeutics (ASX:ANP) and highlights Neuren Pharmaceuticals (ASX:NEU) as a stock with key catalysts ahead.

Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog

On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/morgans.australia
On Twitter: twitter.com/morgansAU